Nyxoah

Nyxoah

Nyxoah was established in 2009 by Olivier Taelman alongside a founding team with deep experience in neuromodulation, aiming to solve a persistent compliance crisis in sleep medicine. Obstructive sleep apnea affects roughly one billion people globally, but the standard-of-care positive-airway-pressure mask records adherence rates below 50% at 12 months. The firm's Genio bilateral hypoglossal nerve stimulation system is designed as a fully implantable, leadless, battery-powered alternative that patients activate externally before sleep. A 2019 European IPO provided capital to scale manufacturing and clinical evidence, with a subsequent 2020 Nasdaq listing broadening the US investor base. The Genio system has received CE Mark clearance in Europe and is distributed in key markets including Germany, Switzerland, and the UK, where reimbursement pathways in public-health systems are being established country by country. Nyxoah's DREAM US pivotal study completed enrollment in 2023, evaluating Genio against a sham control in a randomized withdrawal design. The firm also runs a post-market registry tracking real-world patient adherence and apnea-hypopnea index reduction. Manufacturing takes place in Belgium, and the supply chain relies on specialized implantable-grade components sourced from European and Israeli medtech suppliers. Beyond the DREAM study, Nyxoah initiated the ACCCESS trial in 2023 for complete concentric collapse patients previously contraindicated for hypoglossal stimulation, potentially expanding the addressable market by 30-40%. The company reported €1.8 million in third-quarter 2024 revenue, reflecting early German hospital tenders and increasing implant volumes. External collaborators have included academic sleep centers such as Charité Berlin and clinical investigators who previously worked on the Inspire Medical Systems trials, creating a cross-pollinated researcher network. Nyxoah has not disclosed any philanthropic or family-office backing, operating purely as a venture-backed then publicly funded commercial-stage company. Nyxoah's structural differentiator is the Genio implant's external activation patch, which eliminates the need for a surgical pocket for an internal battery-communication module—the approach taken by its main competitor. This design shortens operating time, improves MRI compatibility, and allows future device upgrades without explant surgery. The dual-listing structure on Euronext and Nasdaq also provides a capital-markets pipeline distinct from the venture-private-equity route, with regulatory catalysts dictating liquidity windows rather than fund-life cycles.